CancerDrs

Lung Cancer clinical trials in California

132 actively recruiting lung cancer trials at 106 sites across California.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in California:
  • Kaiser Permanente-Anaheim — Anaheim, California
  • Kaiser Permanente-Deer Valley Medical Center — Antioch, California
  • Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
  • PCR Oncology — Arroyo Grande, California
  • Sutter Auburn Faith Hospital — Auburn, California
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in California:
  • Kaiser Permanente Dublin — Dublin, California
  • Kaiser Permanente-Fremont — Fremont, California
  • Kaiser Permanente Fresno Orchard Plaza — Fresno, California
  • Kaiser Permanente-Fresno — Fresno, California
  • Kaiser Permanente- Modesto MOB II — Modesto, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in California:
  • Oncura Health - Anaheim — Anaheim, California
  • Memorial Care Orange Coast Medical Center Attn — Fountain Valley, California
  • MemorialCare Orange Coast Medical Center — Fountain Valley, California
  • OC Blood and Cancer Care — Fountain Valley, California
  • Oncura Health - Fountain Valley — Fountain Valley, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in California:
  • Providence - Saint Joseph Home Health - Anaheim — Anaheim, California
  • The Oncology Institute of Hope and Innovation - Corporate Office — Cerritos, California
  • Local Institution - 007-777 — Fountain Valley, California
  • Local Institution - 007-778 — Laguna Hills, California
  • Local Institution - 007-898-B — Long Beach, California
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in California:
  • Tower Cancer Research Foundation — Beverly Hills, California
  • Cedars-Sinai Medical Center — Los Angeles, California
  • Cedars-Sinai Cancer - Tarzana — Tarzana, California
  • Torrance Memorial Physician Network - Cancer Care — Torrance, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in California:
  • Clinical Study Site — Alameda, California
  • Clinical Study Site — Anaheim, California
  • Clinical Study Site — Beverly Hills, California
  • Clinical Study Site — Cerritos, California
  • Clinical Study Site — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in California:
  • UCLA Hematology/Oncology - Santa Monica — Los Angeles, California
  • Profound Research LLC — Oceanside, California
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
  • Stanford Cancer Center — Palo Alto, California
  • Kaiser Permanente San Diego Mission Road — San Diego, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or …

Sponsor: AstraZeneca
NCT ID: NCT06627647
Sites in California:
  • Research Site — Anaheim, California
  • Research Site — Beverly Hills, California
  • Research Site — Loma Linda, California
  • Research Site — Redlands, California
  • Research Site — San Diego, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • City of Hope at Irvine Lennar — Irvine, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in California:
  • Community Cancer Institute (CCI) — Clovis, California
  • Marin Cancer Care Inc — Greenbrae, California
  • UCI Health-CIACC — Irvine, California
  • UCLA Oncology Center — Los Angeles, California
  • Hoag Memorial Hospital — Newport Beach, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in California:
  • Research Site — Anaheim, California
  • Research Site — Beverly Hills, California
  • Research Site — Fountain Valley, California
  • Research Site — Newport Beach, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in California:
  • UC San Diego Health System - Encinitas — Encinitas, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • UC San Diego Medical Center - Hillcrest — San Diego, California
  • California Protons Cancer Therapy Center — San Diego, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in California:
  • Local Institution - 0112 — Los Angeles, California
  • University of California Davis (UC Davis) Comprehensive Cancer Center — Sacramento, California
  • Local Institution - 0159 — San Francisco, California
  • UCLA Hematology/Oncology - Santa Monica — Santa Monica, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312137
Sites in California:
  • Beverly Hills Cancer Center ( Site 0070) — Beverly Hills, California
  • The Angeles Clinic and Research Institute ( Site 0040) — Los Angeles, California
  • The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate ( Site 0079) — Los Angeles, California
  • UCLA Clinical & Translational Research Center (CTRC) ( Site 0033) — Los Angeles, California
  • Hoag Memorial Hospital Presbyterian ( Site 0096) — Newport Beach, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…

Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in California:
  • Research Site — Duarte, California
  • Research Site — Irvine, California
  • Research Site — La Jolla, California
  • Research Site — Loma Linda, California
  • Research Site — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in California:
  • City of Hope (Adults and Pediatrics) — Duarte, California
  • University of California San Diego Moores Cancer Center (Adults only) — La Jolla, California
  • Loma Linda University Medical Center (Adults only) — Loma Linda, California
  • Children's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics) — Los Angeles, California
  • UCLA Medical Center (Adults and Pediatrics) — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in California:
  • University of California San Diego — La Jolla, California
  • UC Davis Comprehensive Cancer Center — Sacramento, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Sponsor: AstraZeneca
NCT ID: NCT06417814
Sites in California:
  • Research Site — Duarte, California
  • Research Site — Fountain Valley, California
  • Research Site — La Jolla, California
  • Research Site — Los Angeles, California
  • Research Site — San Diego, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in California:
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building — Irvine, California
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer …

Sponsor: Bayer
NCT ID: NCT06452277
Sites in California:
  • Patty & George Hoag Cancer Center — Newport Beach, California
  • UC San Diego Health - Moores Cancer Center — San Diego, California
  • UCSF Bakar Precision Cancer Medicine Building - Thoracic Surgery and Oncology — San Francisco, California
  • UCLA Health Santa Monica Cancer Care — Santa Monica, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity "when telisotuzumab adizutecan i…

Sponsor: AbbVie
NCT ID: NCT07005102
Sites in California:
  • City of Hope National Medical Center /ID# 282241 — Duarte, California
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 284734 — Irvine, California
  • USC Norris Comprehensive Cancer Center /ID# 275343 — Los Angeles, California
  • Usc Norris Oncology/Hematology Treatment Center /ID# 278673 — Newport Beach, California
  • UCLA - Santa Monica /ID# 276816 — Santa Monica, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Sponsor: Eikon Therapeutics
NCT ID: NCT07365319
Sites in California:
  • Los Angeles Cancer Network — Glendale, California
  • Providence St. Joseph Hospital — Orange, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan an…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06170788
Sites in California:
  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130) — Burbank, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…

Sponsor: InSightec
NCT ID: NCT05317858
Sites in California:
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses o…

Sponsor: Takeda
NCT ID: NCT07217301
Sites in California:
  • Apex Research — Fair Oaks, California
  • Memorial Care — Fountain Valley, California
  • Cancer and Blood Specialty Clinic — Los Alamitos, California
  • Translation Research in Oncology- US, INC (TRIO-US) — Torrance, California
View on ClinicalTrials.gov →

Showing 25 of 132 trials with sites in California. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12